Direxion Daily Healthcare Bull 3X ETF (CURE)
| Assets | $198.86M |
| Expense Ratio | 0.94% |
| PE Ratio | 26.85 |
| Forward PE | n/a |
| Shares Out | 1.20M |
| Dividend | $1.26 (0.75%) |
| Ex-Dividend Date | Sep 22, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 20.27% |
| Volume | 99,886 |
| Open | 172.96 |
| Previous Close | 165.37 |
| Day's Range | 168.16 - 175.00 |
| 52-Week Low | 82.41 |
| 52-Week High | 175.68 |
| Beta | 1.55 |
| Holdings | 68 |
| Inception Date | Jun 15, 2011 |
About CURE
Fund Home PageThe Direxion Daily Healthcare Bull 3X ETF (CURE) is an exchange-traded fund that is based on the S&P Health Care Select Sector index. The fund provides 3x levered exposure to a market cap weighted sub-index of the S&P 500 that tracks the performance of US listed health care companies. CURE was launched on Jun 15, 2011 and is issued by Direxion.
Top 10 Holdings
289.84% of assets| Name | Symbol | Weight |
|---|---|---|
| IXV SWAP ASSET LEG | n/a | 90.83% |
| IXV SWAP ASSET LEG | n/a | 58.52% |
| IXV SWAP ASSET LEG | n/a | 43.07% |
| IXV SWAP ASSET LEG | n/a | 38.46% |
| DREYFUS GOVT CASH MAN INS | n/a | 18.98% |
| Eli Lilly and Company | LLY | 11.40% |
| GOLDMAN FINL SQ TRSRY INST 506 | n/a | 8.51% |
| GOLDMAN SACHS FIN GOV 465 INSTITUT | n/a | 7.86% |
| Johnson & Johnson | JNJ | 6.88% |
| AbbVie Inc. | ABBV | 5.33% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 22, 2026 | $0.3152 | Sep 29, 2026 |
| Jun 23, 2026 | $0.3746 | Jun 30, 2026 |
| Mar 24, 2026 | $0.28317 | Mar 31, 2026 |
| Dec 23, 2025 | $0.29121 | Dec 31, 2025 |
| Sep 23, 2025 | $0.31013 | Sep 30, 2025 |
| Jun 24, 2025 | $0.30549 | Jul 1, 2025 |
Performance
CURE had a total return of 84.98% in the past year, including dividends. Since the fund's inception, the average annual return has been 26.64%.
News
Top Performing Leveraged/Inverse ETFs: 10/25/2026
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Biocure Technology Inc. enters into exclusive Letter Agreement to acquire Glorious Success Limited in Reverse Takeover Transaction
VANCOUVER, British Columbia - TheNewswire - June 22 , 2026 -- Biocure Technology Inc. (“CURE” or the “Company”) (CSE: CURE) announces that it has entered into a binding letter agreement dated June 22...